These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Citrome L, Ketter TA, Cucchiaro J, Loebel A. J Affect Disord; 2014 Feb; 155():20-7. PubMed ID: 24246116 [Abstract] [Full Text] [Related]
5. Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis. Kadakia A, Dembek C, Heller V, Singh R, Uyei J, Hagi K, Nosaka T, Loebel A. BMC Psychiatry; 2021 May 11; 21(1):249. PubMed ID: 33975574 [Abstract] [Full Text] [Related]
6. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. Gao K, Kemp DE, Fein E, Wang Z, Fang Y, Ganocy SJ, Calabrese JR. J Clin Psychiatry; 2011 Aug 11; 72(8):1063-71. PubMed ID: 21034695 [Abstract] [Full Text] [Related]
8. Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis. Ostacher M, Ng-Mak D, Patel P, Ntais D, Schlueter M, Loebel A. World J Biol Psychiatry; 2018 Dec 11; 19(8):586-601. PubMed ID: 28264635 [Abstract] [Full Text] [Related]
10. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. Gao K, Ganocy SJ, Gajwani P, Muzina DJ, Kemp DE, Calabrese JR. J Clin Psychiatry; 2008 Feb 11; 69(2):302-9. PubMed ID: 18211129 [Abstract] [Full Text] [Related]
11. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial. Cutler AJ, Datto C, Nordenhem A, Minkwitz M, Acevedo L, Darko D. Clin Ther; 2011 Nov 11; 33(11):1643-58. PubMed ID: 22054797 [Abstract] [Full Text] [Related]
13. Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan. Kishi T, Yoshimura R, Sakuma K, Okuya M, Iwata N. Neuropsychopharmacol Rep; 2020 Dec 11; 40(4):417-422. PubMed ID: 32902200 [Abstract] [Full Text] [Related]
15. Cost-effectiveness of lurasidone vs quetiapine extended-release (XR) in patients with bipolar depression. Rajagopalan K, Meyer K, O'Day K, Denno M, Loebel A. J Med Econ; 2015 Dec 11; 18(10):821-7. PubMed ID: 25985265 [Abstract] [Full Text] [Related]
17. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Citrome L. Postgrad Med; 2010 Jul 11; 122(4):39-48. PubMed ID: 20675970 [Abstract] [Full Text] [Related]
18. Clinical highlights in bipolar depression: focus on atypical antipsychotics. Calabrese JR, Elhaj O, Gajwani P, Gao K. J Clin Psychiatry; 2005 Jul 11; 66 Suppl 5():26-33. PubMed ID: 16038599 [Abstract] [Full Text] [Related]